2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Role of AI in Cancer Research and Care
- AI in Early Detection and Diagnosis
- AI in Personalized Cancer Therapies
- AI in Radiation and Surgical Oncology
- AI in Cancer Research and Drug Development
- AI for Predictive Analytics in Cancer Care
Artificial Intelligence (AI) is revolutionizing cancer research and care by enabling more accurate diagnoses, personalized treatments, and enhanced patient outcomes. Machine learning algorithms are being used to analyze vast amounts of medical data, such as imaging scans and genetic profiles, to detect early signs of cancer that might be missed by human clinicians. AI also aids in identifying potential biomarkers and predicting how cancers will respond to various therapies, allowing for the development of tailored treatment plans. Moreover, AI-driven systems can automate administrative processes, boosting efficiency and reducing the workload in oncology clinics. As AI continues to evolve, its ability to uncover new insights in cancer biology and treatment holds immense potential, making it an essential tool in the fight against cancer.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China